← Human Trials & Peer-Reviewed Studies
Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition
Plain-language guide to PMID 24516103 (2014): double-blind randomized controlled trial study of Bradykinin and Substance P.
Key Facts
- PMID
- 24516103
- Journal
- Hypertension (Dallas, Tex. : 1979)
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Devin JK et al. (6 authors)
- DOI
- 10.1161/HYPERTENSIONAHA.113.02767
What This Study Did, in Plain Language
What Was Tested
Researchers studied Bradykinin and Substance P in this randomized controlled trial publication.
Dipeptidyl peptidase-4 degrades other peptides with a penultimate proline or alanine, including bradykinin and substance P, which are also substrates of angiotensin-converting enzyme (ACE).
During ACE inhibition, substance P is inactivated primarily by dipeptidyl peptidase-4, whereas bradykinin is first inactivated by aminopeptidase P.
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.
The participants were allocated by chance, so the Bradykinin group and the comparison group should start out alike.
As a double-blind Bradykinin study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Bradykinin group a baseline to be compared against.
Each person switched between Bradykinin and the comparison at some point, usually with a gap in between.
What Was Measured
This study tested the hypothesis that dipeptidyl peptidase-4 inhibition potentiates vasodilator and fibrinolytic responses to substance P when ACE is inhibited.
PubMed files the paper under topics including Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Bradykinin, Dipeptidyl Peptidase 4, Enalaprilat, Enzyme Inhibitors and Heart Rate.
Author keywords: diabetes mellitus, dipeptidyl peptidase-4, hypertension, norepinephrine, renin–angiotensin system and vasodilation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Bradykinin and Substance P.
The publication is from 2014 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.
More context: the Bradykinin compound page and the Substance P compound page, all human trials.
Our Notes on the Compounds
Bradykinin: A 9-amino-acid peptide that widens blood vessels and causes swelling; given in research studies of blood flow.
Substance P: An 11-amino-acid neuropeptide involved in pain signaling and inflammation; given in research studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.